InvestorsHub Logo
Followers 4
Posts 1242
Boards Moderated 0
Alias Born 01/16/2016

Re: abira post# 6035

Sunday, 08/04/2019 1:23:43 PM

Sunday, August 04, 2019 1:23:43 PM

Post# of 6602
Good catch on the revaluation. I think there's another interpretation to the Earnings Report though. If the GT just reached market saturation at the current price, moving production to China might have been perfectly timed. Seems likely the easiest way to increase demand for the GT is by lowering prices.

Simultaneously introducing another product (UE) to be made in China is also ideal timing, before production truly starts - assuming this is the game plan. A major bottle neck of the GT is the therapist training, which may not be necessary with the UE.

I think the philosophical implications on future success resulting from going into upper extremity exoskeletons are also profound. My understanding of the physics is that in order to make an efficient full body suit, understanding the higher level kinematics of the upper body are equally, if not more important than lower body motion alone. This could be a major competitive edge for Ekso going forward.

Another factor related to their cost cutting to consider has do with scaling. I think it's clearly better focus on efficiency before attempting to scale than compared to afterwards. Seeing efficiency move in the right direction gives me more faith that future growth will be handled properly.

I believe Ekso is at a critical juncture between initial product development and scaled mass production. I think the big investments the company is making will pay off and I'm holding long.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EKSO News